AbbVie Submits FDA Application for Upadacitinib (RINVOQ) to Treat Severe Alopecia Areata

Key Takeaways

• AbbVie has submitted an FDA application for upadacitinib (RINVOQ) to treat severe alopecia areata in adults and adolescents
• Phase 3 UP-AA clinical trials met primary endpoint with SALT score ≤20 at week 24, with sustained results at week 52
• Upadacitinib is the first JAK inhibitor to achieve complete scalp hair regrowth (SALT=0) as a secondary endpoint at week 24

---

AbbVie Advances Alopecia Areata Treatment with FDA Submission

AbbVie (NYSE: ABBV) announced on April 28, 2026, that it has submitted a regulatory application to the U.S. Food and Drug Administration (FDA) seeking approval for upadacitinib (RINVOQ®) as a treatment for severe alopecia areata in adults and adolescents.

Phase 3 Trial Results Drive Regulatory Submission

The FDA submission is supported by robust data from the Phase 3 UP-AA clinical program, which demonstrated significant efficacy in treating this autoimmune condition that causes patchy hair loss. The trials successfully met their primary endpoint, with patients achieving a Severity of Alopecia Tool (SALT) score of ≤20 at week 24, indicating substantial hair regrowth.

Notably, the positive results were sustained through week 52, suggesting long-term treatment benefits for patients with this challenging condition.

First-in-Class Achievement for JAK Inhibitors

Upadacitinib distinguished itself as the first JAK (Janus kinase) inhibitor to meet the ranked secondary endpoint of complete scalp hair regrowth, defined as a SALT score of 0, at the 24-week mark. This milestone represents a significant advancement in alopecia areata treatment, as complete hair regrowth has been historically difficult to achieve.

Market Impact and Patient Implications

Alopecia areata affects approximately 6.8 million people in the United States, with severe cases causing significant psychological distress and reduced quality of life. Currently approved treatments are limited, creating substantial unmet medical need in this patient population.

Upadacitinib is already approved for multiple inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis. An approval for alopecia areata would expand the drug’s market reach and provide patients with a new therapeutic option backed by clinical evidence.

Regulatory Timeline and Next Steps

The FDA will now review AbbVie’s submission, which includes comprehensive safety and efficacy data from the Phase 3 program. The regulatory review process typically takes 10-12 months for standard applications, though the timeline may vary based on FDA priorities and any additional data requests.

---

Frequently Asked Questions

What does this FDA submission mean for alopecia areata patients?

This submission could lead to the first JAK inhibitor approved specifically for severe alopecia areata, offering patients a new treatment option that demonstrated complete hair regrowth in clinical trials.

When will upadacitinib be available for alopecia areata treatment?

If approved, upadacitinib could be available for alopecia areata treatment within 10-12 months, pending FDA review of AbbVie’s application and any additional regulatory requirements.

How does upadacitinib compare to existing alopecia areata treatments?

Upadacitinib is the first JAK inhibitor to achieve complete scalp hair regrowth (SALT=0) in Phase 3 trials, potentially offering superior efficacy compared to current limited treatment options for severe alopecia areata.

Related coverage

• AbbVie Cerevel acquisition closes in $8.7B neuroscience deal
• AbbVie closes $8.7B Cerevel deal as neuroscience pipeline expands